Reviva Pharmaceuticals Holdings (RVPH) Short-Term Debt issuances (2023 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Short-Term Debt issuances of $175601.0 for Q1 2026, up 55.06% sequentially from $113246.0 in Q3 2025, and down 24.91% YoY from $233854.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Short-Term Debt issuances (2023 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Short-Term Debt issuances for 4 years, with the latest figure at $175601.0 in Q1 2026.
- Quarterly Short-Term Debt issuances fell 24.91% year-over-year to $175601.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $399901.0 (down 49.75% YoY) and the FY2025 annual result came in at $458154.0, down 53.1% from the prior year.
- Short-Term Debt issuances advanced to $175601.0 in Q1 2026 per RVPH's latest filing, from $113246.0 in the prior quarter.
- Over five years, Short-Term Debt issuances peaked at $667500.0 in Q1 2023 and troughed at -$222500.0 in Q2 2023.
- A 4-year average of $253128.8 and a median of $222500.0 in 2023 frame the typical range for Short-Term Debt issuances.
- The sharpest annual moves came in 2025 and 2026: Short-Term Debt issuances tumbled 43.65% in 2025, then fell 24.91% in 2026.
- Over 4 years, Short-Term Debt issuances stood at $222500.0 in 2023, then soared by 152.54% to $561904.0 in 2024, then sank by 79.85% to $113246.0 in 2025, then jumped by 55.06% to $175601.0 in 2026.
- According to Business Quant data, Short-Term Debt issuances over the past three periods registered $175601.0, $113246.0, and $111054.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 87,181.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87,181.00 |
| Jun 30, 2026 | 87,181.00 |
| Mar 31, 2026 | 175,601.00 |
| Mar 31, 2026 | 175,601.00 |
| Sep 30, 2025 | 113,246.00 |
| Sep 30, 2025 | 113,246.00 |
| Jun 30, 2025 | 111,054.00 |
| Jun 30, 2025 | 111,054.00 |
| Mar 31, 2025 | 233,854.00 |
| Mar 31, 2025 | 233,854.00 |
| Dec 31, 2024 | 561,904.00 |
| Dec 31, 2024 | 561,904.00 |
| Mar 31, 2024 | 415,000.00 |
| Mar 31, 2024 | 415,000.00 |
| Sep 30, 2023 | 222,500.00 |
| Sep 30, 2023 | 222,500.00 |
| Jun 30, 2023 | -222,500.00 |
| Jun 30, 2023 | -222,500.00 |
| Mar 31, 2023 | 667,500.00 |
| Mar 31, 2023 | 667,500.00 |